Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy
    ABSTRACT & COMMENTARY

    Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy

    January 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy

    COVID-19 Affected U.S. Life Expectancy: How Bad Is It?

    Association of Sleepwalking and REM Sleep Behavior Disorder in Men with Parkinson’s

    Related Products

    Differences in Disease Duration in LBD May Be Related to Pathologic Burden

    Association of Traumatic Brain Injury with Late-life Neurodegenerative Diseases

    Keywords

    sleep

    mortality

    duration

    nrem

    By Alan Z. Segal, MD

    Associate Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Segal reports no financial relationships relevant to this field of study.

    SYNOPSIS: Total sleep duration declines with increasing age, as does the fraction of sleep spent in rapid eye movement (REM) sleep. The decline in REM is associated with increasing mortality, but it is not clear if this is a cause or a marker of declining health and declining brain function.

    SOURCE: Leary EB, Watson KT, Ancoli-Israel S, et al. Association of rapid eye movement sleep with mortality in middle-aged and older adults. JAMA Neurol 2020;77:1241.

    Although the precise physiological benefit of sleep remains poorly understood, lack of sleep has multiple consequences, including cardiovascular disease, depression, impairments in cognition, and overall mortality. Much of sleep research uses subjects’ self-reporting of sleep duration and quality, but cannot address details such as sleep stages, e.g., differentiating between rapid eye movement (REM) and non-REM (NREM) sleep. Although wearable technologies (such as Fitbit, Whoop, or Apple Watch) increasingly are capable of using accelerometry and pulse oximetry monitoring to accurately identify sleep stages, polysomnography remains the gold standard in quantification of REM and NREM (stages 1, 2, or 3) sleep. The two large, prospective cohorts studied here gathered valuable comprehensive polysomnography data and can be considered among the “Framingham Studies” of sleep research. Now approximately 20 years old, the Outcomes of Sleep Disorders in Older Men (MrOS) and the Wisconsin Sleep Cohort (WSC) both are showing a rising degree of mortality over time and, therefore, increasingly are capable of providing insight into this crucial outcome measure.

    There are important differences between MrOS and WSC. MrOS enrolled 2,675 subjects, all men, and generally older (mean age of 76 years at enrollment between 2003 and 2005). Overall, 52% of the MrOS cohort has died. In contrast, WSC, with a total of 1,386 subjects, enrolled men and women roughly equally and had a mean age of 51 years at enrollment in 1998. Both studies showed a relationship between REM sleep and longevity. MrOS showed a 13% increase in mortality for every 5% reduction in REM sleep. Men achieving < 15% REM sleep showed a mortality hazard ratio (HR) of 1.35 compared to those who spent > 15% of their sleep in REM. WSC had a longer period of follow up (on average, 20 years compared to 12 years in MrOS), but overall mortality was only 13%, given that it studied younger patients. WSC showed a 1.17 HR of death among those with < 15% of the night in REM sleep. Additionally, both studies showed that the mortality benefit was specifically the result of REM duration rather than overall sleep quantity. Results were comparable whether subjects slept for shorter (five- to seven-hour) compared to longer (six- to eight-hour) periods. REM duration ranged from 0% to 44% (19% on average) in MrOS and 0% to 43% (18% on average) in WSC. All of these data were statistically significant, controlling for covariables, such as race/ethnicity, educational level, body mass index, hypertension, smoking status, alcohol, caffeine, and use of sleep aids.

    COMMENTARY

    The results reported here were similarly shown in the Sleep Heart Health Study (SHHS), a large cohort study of 6,600 subjects with obstructive sleep apnea (OSA).1 However, in SHHS, the benefit of REM sleep was found only in women, likely because of the overwhelmingly deleterious effect of OSA among male subjects. Other studies of REM vs. NREM sleep have cast doubt on the specificity of REM as a marker of effective sleep. Although some have shown benefits of REM for cognitive performance and mood, others suggest that total sleep time, or quantity of slow wave (stage 3) sleep rather than REM, seemed more favorable in the prevention of obesity and the metabolic syndrome. As the authors observed, the results reported here are generalizable, given that they were replicated in two well-validated cohorts, diverse in gender and age. They also pointed out obvious weaknesses, including that both studies were more than 90% of white ethnicity. The authors also acknowledged one of the thorniest issues in this type of sleep research — that is, reverse causality. It remains unknown whether REM sleep is merely a marker of brain and overall physical health, rather than a direct cause of longevity.

    REFERENCE

    1. Butler MP, Emch JT, Rueschman M, et al. Apnea-hypopnea event duration predicts mortality in men and women in the Sleep Heart Health Study. Am J Respir Crit Care Med 2019;99:903-912.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 5) - January 2021
    January 1, 2021

    Table Of Contents

    Neurotropism of COVID-19: What Is New?

    Cranial Neuropathy in CIDP

    Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy

    Rhabdomyolysis Etiology

    Medical Therapy vs. Carotid Endarterectomy in Patients with Asymptomatic Carotid Stenosis

    Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke

    A Mobile Interventional Stroke Team (MIST) Shows Promise in Performing Rapid Thrombectomy

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing